Insulin-like growth factor I reduces lipid oxidation and foam cell formation via downregulation of 12/15-lipoxygenase

Atherosclerosis

Volumn 238, Issue 2, 2015, Pages 313-320

  Sukhanov, Sergiy ^a   Snarski, Patricia ^a   Vaughn, Charlotte ^a   Lobelle Rich, Patricia ^a   Kim, Catherine ^a   Higashi, Yusuke ^a   Shai, Shaw Yung ^a   Delafontaine, Patrice ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Foam cells; LDL Oxidation antioxidants; Lipoxygenase; Macrophages monocytes; Oxidized lipids

Indexed keywords

APOLIPOPROTEIN E; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; MESSENGER RNA; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN C; STAT6 PROTEIN; 12-15-LIPOXYGENASE; IGF1 PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN; STAT6 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; FOAM CELL; HUMAN; HUMAN CELL; INFLAMMATION; INTERNALIZATION; LIPID BLOOD LEVEL; LIPID OXIDATION; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PERITONEUM MACROPHAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THP 1; UPREGULATION; ANIMAL; ATHEROSCLEROSIS; BLOOD; C57BL MOUSE; CELL LINE; DEFICIENCY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

ANIMALS; APOLIPOPROTEINS E; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONATE 15-LIPOXYGENASE; ATHEROSCLEROSIS; CELL LINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FOAM CELLS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INSULIN-LIKE GROWTH FACTOR I; LIPOPROTEINS, LDL; MACROPHAGES, PERITONEAL; MICE, INBRED C57BL; MICE, KNOCKOUT; PHOSPHATIDYLINOSITOL 3-KINASE; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT6 TRANSCRIPTION FACTOR;

EID: 84920074196     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.12.024     Document Type: Article

References (38)

1. Parthasarathy S., Steinberg D., Witztum J.L. The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis. Annu. Rev. Med. 1992, 43:219-225.
2. Yu X.H., et al. Foam cells in atherosclerosis. Clin. Chim. Acta 2013, 424:245-252.
3. Funk C.D. Lipoxygenase pathways as mediators of early inflammatory events in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2006, 26(6):1204-1206.
4. Cyrus T., et al. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J.Clin. Invest. 1999, 103(11):1597-1604.
5. Cyrus T., et al. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. Circulation 2001, 103(18):2277-2282.
6. George J., et al. 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. Circulation 2001, 104(14):1646-1650.
7. Huo Y., et al. Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004, 110(14):2024-2031.
8. Okura Y., et al. Oxidized low-density lipoprotein is associated with apoptosis of vascular smooth muscle cells in human atherosclerotic plaques. Circulation 2000, 102(22):2680-2686.
9. Okura Y., et al. Decreased expression of insulin-like growth factor-1 and apoptosis of vascular smooth muscle cells in human atherosclerotic plaque. J.Mol. Cell. Cardiol. 2001, 33(10):1777-1789.
10. Delafontaine P., Song Y.H., Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler. Thromb. Vasc. Biol. 2004, 24(3):435-444.
11. Sukhanov S., et al. IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2007, 27(12):2684-2690.
12. Sukhanov S., et al. Differential requirement for nitric oxide in IGF-1-induced anti-apoptotic, anti-oxidant and anti-atherosclerotic effects. FEBS Lett. 2011, 585(19):3065-3072.
13. Shai S.Y., et al. Smooth muscle cell-specific insulin-like growth factor-1 overexpression in Apoe-/- mice does not alter atherosclerotic plaque burden but increases features of plaque stability. Arterioscler. Thromb. Vasc. Biol. 2010, 30(10):1916-1924.
14. Titterington J.S., et al. Growth hormone-releasing peptide-2 suppresses vascular oxidative stress in ApoE-/- mice but does not reduce atherosclerosis. Endocrinology 2009, 150(12):5478-5487.
15. Del Rio D., Stewart A.J., Pellegrini N. Areview of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr. Metab. Cardiovasc. Dis. 2005, 15(4):316-328.
16. Conrad D.J., Lu M. Regulation of human 12/15-lipoxygenase by Stat6-dependent transcription. Am. J. Respir. Cell. Mol. Biol. 2000, 22(2):226-234.
17. Heydeck D., et al. Interleukin-4 and -13 induce upregulation of the murine macrophage 12/15-lipoxygenase activity: evidence for the involvement of transcription factor STAT6. Blood 1998, 92(7):2503-2510.
18. Cui X., et al. Unphosphorylated STAT6 contributes to constitutive cyclooxygenase-2 expression in human non-small cell lung cancer. Oncogene 2007, 26(29):4253-4260.
19. Yan S.J., et al. Unphosphorylated STAT and heterochromatin protect genome stability. FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol. 2011, 25(1):232-241.
20. Yang J., Stark G.R. Roles of unphosphorylated STATs in signaling. Cell Res. 2008, 18(4):443-451.
21. Lougheed M., Steinbrecher U.P. Mechanism of uptake of copper-oxidized low density lipoprotein in macrophages is dependent on its extent of oxidation. J.Biol. Chem. 1996, 271(20):11798-11805.
22. Higashi Y., et al. Aging, atherosclerosis, and IGF-1. J.Gerontol. A Biol. Sci. Med. Sci. 2012, 67(6):626-639.
23. Chernausek S.D., et al. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J.Clin. Endocrinol. Metab. 2007, 92(3):902-910.
24. Clemmons D.R. Role of IGF-I in skeletal muscle mass maintenance. Trends Endocrinol. Metab. 2009, 20(7):349-356.
25. Gasperi M., Castellano A.E. Growth hormone/insulin-like growth factor I axis in neurodegenerative diseases. J.Endocrinol. Investig. 2010, 33(8):587-591.
26. Jones N.L., Reagan J.W., Willingham M.C. The pathogenesis of foam cell formation: modified LDL stimulates uptake of co-incubated LDL via macropinocytosis. Arterioscler. Thromb. Vasc. Biol. 2000, 20(3):773-781.
27. Takahashi Y., Zhu H., Yoshimoto T. Essential roles of lipoxygenases in LDL oxidation and development of atherosclerosis. Antioxid. Redox Signal 2005, 7(3-4):425-431.
28. Brinckmann R., et al. Membrane translocation of 15-lipoxygenase in hematopoietic cells is calcium-dependent and activates the oxygenase activity of the enzyme. Blood 1998, 91(1):64-74.
29. Zhu H., et al. Low density lipoprotein receptor-related protein-mediated membrane translocation of 12/15-lipoxygenase is required for oxidation of low density lipoprotein by macrophages. J.Biol. Chem. 2003, 278(15):13350-13355.
30. Li Y., et al. Insulin-like growth factor-1 receptor activation inhibits oxidized LDL-induced cytochrome C release and apoptosis via the phosphatidylinositol 3 kinase/Akt signaling pathway. Arterioscler. Thromb. Vasc. Biol. 2003, 23(12):2178-2184.
31. Higashi Y., et al. Aredox-sensitive pathway mediates oxidized LDL-induced downregulation of insulin-like growth factor-1 receptor. J.Lipid Res. 2005, 46(6):1266-1277.
32. Song L., et al. Inhibition of 12/15 lipoxygenase by baicalein reduces myocardial ischemia/reperfusion injury via modulation of multiple signaling pathways. Apoptosis 2014, 19(4):567-580.
33. Zhao L., et al. 12/15-Lipoxygenase gene disruption and vitamin E administration diminish atherosclerosis and oxidative stress in apolipoprotein E deficient mice through a final common pathway. Prostagl. Other Lipid Mediat. 2005, 78(1-4):185-193.
34. Chinnici C.M., et al. Absence of 12/15 lipoxygenase reduces brain oxidative stress in apolipoprotein E-deficient mice. Am. J. Pathol. 2005, 167(5):1371-1377.
35. Siu D. Anew way of targeting to treat coronary artery disease. J.Cardiovasc. Med. Hagerst. 2010, 11(1):1-6.
36. Chen S. Natural products triggering biological targets-a review of the anti-inflammatory phytochemicals targeting the arachidonic acid pathway in allergy asthma and rheumatoid arthritis. Curr. Drug Targets 2011, 12(3):288-301.
37. van Leyen K., et al. Novel lipoxygenase inhibitors as neuroprotective reagents. J.Neurosci. Res. 2008, 86(4):904-909.
38. Patrignani P., Tacconelli S. Isoprostanes and other markers of peroxidation in atherosclerosis. Biomarkers 2005, 10(1):S24-S29.